Compare · IDXX vs QDEL
IDXX vs QDEL
Side-by-side comparison of IDEXX Laboratories Inc. (IDXX) and QuidelOrtho Corporation (QDEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IDXX and QDEL operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX is the larger of the two at $44.27B, about 44.9x QDEL ($986.4M).
- Over the past year, IDXX is up 10.3% and QDEL is down 52.5% - IDXX leads by 62.9 points.
- QDEL has been more active in the news (15 items in the past 4 weeks vs 5 for IDXX).
- IDXX has more recent analyst coverage (23 ratings vs 19 for QDEL).
- Company
- IDEXX Laboratories Inc.
- QuidelOrtho Corporation
- Price
- $573.61+2.07%
- $14.34-0.86%
- Market cap
- $44.27B
- $986.4M
- 1M return
- +2.50%
- +32.53%
- 1Y return
- +10.33%
- -52.52%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1991
- News (4w)
- 5
- 15
- Recent ratings
- 23
- 19
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
QuidelOrtho Corporation
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.
Latest IDXX
- Executive Vice President Fennell George converted options into 639 shares and covered exercise/tax liability with 284 shares, increasing direct ownership by 4% to 10,433 units (SEC Form 4)
- SEC Form SD filed by IDEXX Laboratories Inc.
- IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection
- IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
- The Biology Came First.
- IDEXX Laboratories Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Director Samad Sam
- SEC Form 4 filed by Director Vandebroek Sophie V.
- SEC Form 4 filed by Director Peacock Karen
- SEC Form 4 filed by Director Junius Daniel M
Latest QDEL
- Director Strobeck Matthew was granted 6,829 shares, increasing direct ownership by 25% to 34,604 units (SEC Form 4)
- Director Widder Kenneth J was granted 6,829 shares, increasing direct ownership by 18% to 43,890 units (SEC Form 4)
- Director Polan Mary Lake Ph D was granted 6,829 shares, increasing direct ownership by 54% to 19,469 units (SEC Form 4)
- Director Buechler Kenneth F was granted 6,829 shares, increasing direct ownership by 7% to 108,750 units (SEC Form 4)
- Director Chiminski John R was granted 6,829 shares, increasing direct ownership by 271% to 9,352 units (SEC Form 4)
- Director Huennekens R Scott was granted 6,829 shares, increasing direct ownership by 271% to 9,352 units (SEC Form 4)
- Director Wilkins Joseph D Jr. was granted 6,829 shares, increasing direct ownership by 58% to 18,705 units (SEC Form 4)
- Director Rhoads Ann D was granted 6,829 shares, increasing direct ownership by 42% to 23,257 units (SEC Form 4)
- Director Michael Edward L. was granted 6,829 shares, increasing direct ownership by 32% to 28,181 units (SEC Form 4)
- Director Dilsaver Evelyn S was granted 6,829 shares, increasing direct ownership by 64% to 17,453 units (SEC Form 4)